博雅生物2月25日获融资买入1233.54万元，融资余额6.83亿元

Core Viewpoint - Boya Bio's stock performance shows a slight increase, with significant financing activities indicating high investor interest and potential volatility in the market [1][2]. Financing Summary - On February 25, Boya Bio recorded a financing buy amount of 12.34 million yuan, with a net financing purchase of 2.61 million yuan, indicating strong demand for its shares [1]. - The total financing and securities balance reached 686 million yuan, representing 6.07% of the circulating market value, which is above the 80th percentile of the past year [1]. - The company also experienced a high level of short selling, with a short selling balance of 2.73 million yuan, exceeding the 90th percentile of the past year [1]. Business Performance - For the period from January to September 2025, Boya Bio achieved a revenue of 1.47 billion yuan, reflecting a year-on-year growth of 18.38%, while the net profit attributable to shareholders decreased by 16.90% to 343 million yuan [2]. - The company's main business segments include blood products (84.58% of revenue), biochemical drugs (8.63%), distribution business (6.12%), and other businesses (0.65%) [1]. Shareholder Information - As of February 13, the number of shareholders for Boya Bio was 31,600, a decrease of 0.27% from the previous period, while the average circulating shares per person increased by 0.27% to 15,959 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 8.88 million shares, a decrease of 1.82 million shares from the previous period [3].